Coronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study

A Rodriguez, M Rodriguez Alemparte, J Baldi, J Navia, A Delacasa, D Vogel, R Oliveri, C Fernández Pereira, V Bernardi, W O’Neill, I F Palacios, on behalf of the ERACI II Investigators

Purpose: To compare percutaneous coronary intervention (PCI) using stent implantation versus coronary artery bypass graft (CABG) in patients with multiple vessel disease with involvement of the proximal left anterior descending coronary artery (LAD).

Methods: 230 patients with multiple vessel disease and severe stenosis of the proximal LAD (113 with PCI, 117 with CABG). They were a cohort of patients from the randomised ERACI (Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease) II study.

Results: Both groups had similar baseline characteristics. There were no significant differences in 30 day major adverse cardiac events (death, myocardial infarction, stroke, and repeat procedures) between the strategies (PCI 2.7% v CABG 7.6%, p = 0.18). There were no significant differences in survival (PCI 96.4% v CABG 95%, p = 0.98) and survival with freedom from myocardial infarction (PCI 92% v CABG 89%, p = 0.94) at 41.5 (6) months’ follow up. However, freedom from new revascularisation procedures (CABG 96.6% v PCI 73%, p = 0.0002) and freedom of angina (CABG 9.4% v PCI 22%, p = 0.025) were superior in the CABG group.

Conclusion: Patients with multivessel disease and significant disease of the proximal LAD randomly assigned in the ERACI II trial to PCI or CABG had similar survival and survival with freedom from myocardial infarction at long term follow up. Repeat revascularisation procedures were higher in the PCI group.

Several randomised trials comparing balloon angioplasty (percutaneous transluminal coronary angioplasty (PTCA)) versus coronary artery bypass graft (CABG) in patients with multivessel coronary artery disease have shown no significant differences in mortality and in the incidence of acute myocardial infarction between these treatment strategies. CABG has a prognosis advantage over PTCA only in insulin dependent and orally treated diabetic patients. Data from non-randomised studies suggest that the outcome after revascularisation depends on the distribution of revascularisation coronary artery disease. In that regard, the severity and location of left anterior descending coronary artery (LAD) involvement have been identified as important determinants of outcome in patients with coronary artery disease. Several registries of PTCA versus CABG have shown a trend to improved survival with CABG in patients with multiple vessel disease and proximal LAD stenosis. However, a major limitation of these studies is that they were conducted in the era preceding the widespread use of coronary stenting. We recently published the results of the ERACI (Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease) II trial, a randomised comparison of percutaneous coronary intervention (PCI) with liberal use of coronary stents versus CABG in patients with multiple vessel disease. The purpose of the present study was to analyse the immediate and long term outcome of PCI versus CABG in a cohort of patients with multiple vessel disease and significant proximal LAD disease randomised in the ERACI II trial.

MATERIALS AND METHODS

Study population

From 450 patients in the ERACI II study we identified 414 patients with severe stenosis of the LAD; 230 of them had severe (≥ 70%) stenosis in the proximal LAD (from its origin to the takeoff of the first diagonal branch). They constituted the study population. Patients with severe stenosis of the LAD distal to the first diagonal branch were excluded from this analysis.

Details of the ERACI II trial have been previously described. It is of particular importance that > 90% of the patients randomised in this study presented with unstable angina. The primary end point of the study was to compare major adverse cardiac events defined as death, Q wave myocardial infarction, stroke, and repeat PTCA or CABG at 30 days and at one, three, and five years of follow up. Death included mortality from all causes. Secondary end points were follow up angina status, comparison of the completeness of revascularisation as assessed by stress thallium, and follow up cost of the two revascularisation strategies.

Revascularisation techniques

CABG procedure was performed by standard surgical techniques. Complete revascularisation was achieved, when possible, by using arterial conduits and reverse saphenous vein grafts.

Coronary angioplasty and stent deployment were performed using standard techniques as previously described.

Abbreviations: ARTS, artery revascularization strategy study; BARI, bypass angioplasty revascularization investigation; CABG, coronary artery bypass graft; ERACI, Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease; LAD, left anterior descending coronary artery; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; SOS, stent or surgery
Weight based intravenous heparin was given to achieve an activated clotting time > 280 seconds during the procedure. Patients with rest pain in the preceding 48 hours and those with postmyocardial infarction angina received a bolus followed by an infusion of abciximab. Only vessels with a reference diameter > 3 mm by visual estimation were stented electively. Target vessels were stented with the Gianturco Roubin II stent (Cook Inc, Bloomington, Indiana, USA) as the primary device.

Complete anatomical revascularisation was defined as the angiographic absence of a residual stenosis ≥ 70% in any major epicardial vessel after PCI. In the case of CABG it was determined by the number of distal anastomoses in diseased vessels previously identified as target arteries during the planned surgical strategy. Complete functional revascularisation was determined by stress thallium performed in the first month after the initial revascularisation strategy.7

Statistical analysis
Angiographic and clinical outcomes were analysed according to intention to treat. Results are expressed as mean (SD). Continuous variables of the two treatment groups were compared by unpaired two tailed Student’s t test. Categorical variables and the 30 day composite end point of the two groups were compared by the χ2 method. The composite clinical end point during the follow up period was compared by the Kaplan-Meier and Wilcoxon tests with p values calculated according to the log rank test. All tests were two tailed, and p < 0.05 was considered to indicate significance.

RESULTS
Patient population and baseline characteristics
From 230 patients in the ERACI II trial with ostial or proximal LAD stenosis, 113 were randomly assigned to undergo PCI and 117 to CABG. After randomisation eight patients in the CABG group did not receive the index procedure and seven of them crossed over to the PCI group. In contrast, two patients in the PCI group did not receive the index procedure and seven of them crossed over to the CABG group. The planned PCI procedure could be performed.

There were no significant differences in age, sex, and the frequency of current smokers, diabetes, hypercholesterolaemia, unstable angina class IIb, IIb, and C, and previous myocardial infarction between the two groups of patients (table 1). Angiographic characteristics of both groups of patients were also similar, exhibiting a large proportion of two vessels disease (64% in CABG and 62% in PCI, NS).

Revascularisation procedures
Patients in the CABG group each received an average of 2.4 distal anastomoses. A left internal mammary graft to the LAD was used in 93% of the CABG patients. In the PCI group an average of 1.7 stents per patient were used, and 28.3% of PCI patients received a bolus followed by an infusion of abciximab during the procedure.

Results of coronary angioplasty
Successful revascularisation—defined as a successful dilatation of at least one major epicardial vessel (residual stenosis ≥ 30%) without occurrence of death, Q wave myocardial infarction, emergent hospital CABG, or repeat emergent PCI—was achieved in 97.4% of the PCI patients. At least one vessel was successfully treated in all PCI patients. Two vessels were successfully treated in 84.3% of the patients. The planned PCI strategy was successfully accomplished in 93.6% of intended coronary vessels.

Complete anatomical (CABG 81% v PCI 77%, p = 0.862) and functional (CABG 90.2% v PCI 88%, p = 0.995) revascularisation was similar with both revascularisation strategies. Similar functional revascularisation was apparent by comparable normal, reversible, and non-reversible thallium perfusion defect areas in the PCI and CABG groups at 30 day follow up thallium stress test.

In-hospital and 30 day outcomes
There were no significant differences in 30 day mortality (CABG 2.5% v PCI 0%, NS) between the groups of patients. There were three (2.5%) deaths in the CABG group: two patients died during the initial hospitalisation and one patient died within 30 days after randomisation but before the index procedure could be performed.

The 30 day incidence of Q wave myocardial infarction was similar in both groups (PCI 1.8% v CABG 5.1%, NS). The 30 day composite end point of death and myocardial infarction was 1.8% v 7.6% for the PCI and CABG groups, respectively (p = 0.089). While two patients in the PCI group needed an emergent PTCA (one of them suffered a myocardial infarction), no patient in the CABG group required an emergent repeat revascularisation procedure. No patient in either group suffered a periprocedural major stroke. The 30 day composite end point of major adverse cardiac events (death, myocardial infarction, repeat revascularisation procedure, and stroke) was similar in both groups of patients (2.7% v 7.6% for PCI and CABG, respectively, p = 0.18) (table 2).

Late clinical follow up
Patients were followed up clinically for a mean of 41.5 (6) months (range 31–54 months). Clinical follow up data were available for 228 (99.1%) patients. Kaplan-Meier analysis showed similar two year survival (PCI 96.4% v CABG 95%, p = 0.98) with both strategies of revascularisation (fig 1). After hospital discharge, a similar number of patients died in each group (four in the PCI group and three in the CABG group).

Similarly, Kaplan-Meier curves showed comparable survival with freedom from non-fatal myocardial infarction (PCI 92%
v CABG 89%, \( p = 0.94 \) in both groups of patients (fig 2). In contrast, fig 3 shows freedom from new revascularisation procedures was significantly lower with CABG (96.6% v 73%, \( p = 0.0002 \)). As a consequence solely of this greater need for repeat revascularisation procedures with PCI, Kaplan-Meier event-free survival (freedom from death, myocardial infarction, and repeat PTCA or CABG) was better with CABG than with PCI (86.5% v 65%, \( p = 0.005 \)) (fig 4).

Angina occurred more frequently during follow up in the PCI group (22% v 9.4%, \( p = 0.025 \)). Nevertheless, by the end of the follow up period a similar number of patients in each group were either asymptomatic or had angina class I symptoms (PCI 98% v CABG 96.4%, NS). Furthermore, only 6.2% of patients in the PCI group crossed over to the CABG group during follow up.

Diabetic patients treated with PCI (n = 18) or CABG (n = 22) had similar long term survival (PCI 100% v CABG 95.4%). However, there was a trend for greater target vessel revascularisation (33.3% v 13.6%, \( p = 0.27 \)) in diabetic patients treated with PCI.

**Hospital and follow up costs**

Since analysis was performed by intention to treat, group charges included those of the patients that crossed over to the other revascularisation strategy. In Argentina, at the time of the ERACI II study, the average cost was US$4500 for PCI (excluding stents) and $11000 for uncomplicated CABG. These costs included hospital charges (two days for PCI and nine days for CABG), fees, and an honorarium for both procedures. The costs of stents ranged from $2500–$3000. Each additional day in the coronary care unit added a cost of $600–$1100. The use of abciximab in bolus form and 12 hours infusion added a cost of $3000.

With the above numbers, the final 30 day cost was $1 124 300 for the PCI group versus $1 230 500 for the CABG group (\( p = 0.73 \)). During follow up, requirement for additional revascularisation procedures added a cost of $283 000 for the PCI group and $32 000 for the CABG group. There were no significant differences in overall cost per patient for the entire follow up period (PCI $12 472 v CABG $10 790, \( p = 0.18 \)).

**DISCUSSION**

The present study suggests that patients with multiple vessel disease and severe stenosis of the proximal LAD can be effectively treated with either PCI with liberal use of stents or CABG. Although the number of patients in this subset analysis of the ERACI II trial is small, at long term follow up both revascularisation strategies had similar survival, survival with freedom from non-fatal myocardial infarction, and completeness of revascularisation. Thus, both strategies seem equally safe and effective in improving the clinical status of these patients.

In addition, our study shows that even in the current PCI era characterised by high stent utilisation, requirements for repeat revascularisation procedures remain significantly higher with percutaneous interventions that with conventional bypass surgery. However, they are lower than previously reported with the use of conventional balloon angioplasty.1–9 Although the incidence of angina during the entire follow up was more frequent with stents, it decreased over time and by the end of follow up angina class was similar in both groups. Furthermore, in our study only 6% of PCI patients crossed over to surgery during three years of follow up, a value significantly lower than the > 20% previously reported in non-stent series.1–9

Finally, the three year follow up costs for both procedures were similar, suggesting that, compared with CABG, stenting is no longer cost effective. An increase of resource costs for PCI techniques using stents as compared with plain balloon angioplasty used previously in the ERACI I trial is responsible for this finding.10
Comparison with previous studies
Several registries have previously reported that CABG had better survival than PTCA when the proximal segment of the LAD was involved, and suggested that CABG should be the first treatment option in these cases. However, a major limitation of these studies is that they were conducted in the era preceding the widespread use of coronary stenting. Moreover, there are no data from randomised trials to support this recommendation. Furthermore, the presence of LAD stenosis was not identified as a factor of poor survival after PTCA in the seven year BARI (bypass angioplasty revascularization investigation) follow up study.

We recently published the 30 day and one year follow up outcomes of the total cohort of patients randomised in the ERACI II trial. In-hospital results of the ERACII trial showed a higher incidence of major adverse events in the surgical group. In contrast, in the present study of patients with multivessel disease and significant proximal LAD stenosis, in-hospital and 30 day surgical mortality and major adverse cardiac events were similar in both groups of patients and were lower than the rates previously reported for the overall population of the ERACI II trial. As we previously suggested for the ERACI II trial, baseline patient characteristics more likely account for these results. Our cohort of patients with multivessel coronary artery disease and proximal LAD stenosis had similar age, angina status, and presence of diabetes than the overall ERACI II trial group. However, they had a lower incidence of significant triple vessel disease (36% vs 62%, \( p = 0.008 \)) and a lower incidence of associated peripheral vascular disease (15% vs 27%, \( p = 0.042 \)) than the overall cohort of ERACI II patients. Diffuse coronary artery disease and concomitant peripheral vascular disease are well recognised comorbidities associated with an increased hospital surgical risk. Moreover, the results of the present study are in agreement with those of the ARTS (artery revascularization strategy study) trial showing no significant differences in mortality between the two modalities. In fact our hypothesis is supported by the similar angiographic characteristics of the ARTS and the cohort of patients of the ERACI II trial with proximal LAD stenosis (33% vs 36% incidence of triple vessel disease, respectively). Our results and those of the ARTS trial are in contrast with those of the SOS (stent or surgery) trial showing an increased mortality in the stent arm.

Role of coronary stenting
The use of stents during coronary angioplasty has been shown to reduce acute complications during the initial procedure. The liberal use of stents in this study explains why emergent CABG and acute closure were significantly lower than the rates previously reported for the overall cohort of patients randomised in the ERACI II trial. In-hospital results of the ERACI II trial showed a higher incidence of major adverse events in the surgical group. In contrast, in the present study of patients with multivessel disease and significant proximal LAD stenosis, in-hospital and 30 day surgical mortality and major adverse cardiac events were similar in both groups of patients and were lower than the rates previously reported for the overall population of the ERACI II trial. As we previously suggested for the ERACI II trial, baseline patient characteristics more likely account for these results. Our cohort of patients with multivessel coronary artery disease and proximal LAD stenosis had similar age, angina status, and presence of diabetes than the overall ERACI II trial group. However, they had a lower incidence of significant triple vessel disease (36% vs 62%, \( p = 0.008 \)) and a lower incidence of associated peripheral vascular disease (15% vs 27%, \( p = 0.042 \)) than the overall cohort of ERACI II patients. Diffuse coronary artery disease and concomitant peripheral vascular disease are well recognised comorbidities associated with an increased hospital surgical risk. Moreover, the results of the present study are in agreement with those of the ARTS (artery revascularization strategy study) trial showing no significant differences in mortality between the two modalities. In fact our hypothesis is supported by the similar angiographic characteristics of the ARTS and the cohort of patients of the ERACI II trial with proximal LAD stenosis (33% vs 36% incidence of triple vessel disease, respectively). Our results and those of the ARTS trial are in contrast with those of the SOS (stent or surgery) trial showing an increased mortality in the stent arm.

Limitations of the study
This study was a retrospective analysis of a randomised subpopulation of the ERACI II trial. It is a post hoc analysis of a subgroup of patients with proximal LAD stenosis, which was not predefined in the original ERACI II trial. The number of patients is small with only 280 patients eligible for this subset analysis. In this trial the Gianturco Roubin II stent was used. This coil design stent has been shown to have a higher restenosis rate than slotted tube stents. Thus, the incidence of new revascularisation procedures may have been lower had a tubular stent design been used instead. Finally, this study was performed in the pre-eluting stent era. Applying the results from eluting stent studies to patients with multiple vessel disease should decrease the need for repeat revascularisation procedures, which is the only disadvantage of PCI compared with CABG.

ACKNOWLEDGEMENTS
This study was supported by an unrestricted grant from Cook, Inc (Bloomington, Indiana, USA).

APPENDIX: STUDY ORGANISATION AND PARTICIPANTS
Steering Committee: Alfredo Rodriguez MD PhD FACC, William O’Neill MD FACC, Igor Palacios MD FACC, Liliana Grinfeld MD FACC, José Nava MD FACC, Raul Oliveri MD, Néstor Pérez Balinño MD FACC, Julio Baldi MD.

Safety Committee: Marcelo Elizari MD FACC, Jorge Lerman MD FACC.

Coordinating centre: CECI: Alfredo Rodriguez MD PhD FACC, Víctor Bernardi MD, Sandra Saavedra MD, Máximo Rodriguez Alemparte MD, Cecilia Espinosa BS.

Core laboratory: Carlos Fernández Pereira MD, Omar Sentaera MD.

Statistics: Ulises Questa MD PhD, Larry Harrell BS.

Clinical Events Committee: Rutí Oliveri MD, Néstor Pérez Balinño MD FACC, Eduardo Mele MD FACC, Marcelo Garrido MD, Daniel Vogel MD.

Writing Committee: Alfredo Rodriguez MD PhD FACC, José Nava MD FACC, Igor Palacios MD FACC, William O’Neill MD FACC.

Participating centres:
Sanatorio Otamendi: Carlos Muavec MD, Miguel Russo Felsen MD, Jorge Caviglia MD, Ruben Dayan MD; Sanatorio Ancherena: Diego Guastavino MD, Ernesto Peoyregne MD; Hospital Español: Alberto Cristina MD, Fernando Boullon MD; Clinica Provincial: Omar Sentaera MD, Luis Pringles MD; Clínica Belgrano: Omar Sentaera MD, Alejandro Delacasa MD, Marcelo Martinez Peralta MD; Hospital Italiano: Liliana Grinfeld MD, Daniel Berrocal MD, Jose Gabay MD, Felix Fabrykant MD, Roberto Grinfeld MD; Clínica Olivos: Antonio Pocovi MD, Alberto Domenech MD.

Authors’ affiliations
A Rodriguez, M Rodriguez Alemparte, J Baldi, J Nava, A Delacasa, D Vogel, R Oliveri, C Fernandez Pereira, V Bernardi, Otomendi Hospital, Buenos Aires, Argentina.
REFERENCES

1 Rodriguez A, Bouillon F, Perez Ballito N, et al. Argentine randomized
trial of percutaneous transluminal coronary angioplasty versus coronary
artery by pass surgery in multivessel disease (ERACI): in-hospital results

2 King SB III, Lembo N, Weintraub, et al. A randomized trial comparing
coronary angioplasty with coronary bypass surgery. Emory angioplasty

3 RITA trial participants. Coronary angioplasty versus coronary artery
bypass surgery: the randomized intervention treatment of angina (RITA)

4 CABRI trial participants. Coronary angioplasty vs. bypass
revascularization investigation (CABRI) results during the first year. Lancet

5 Hamm CW, Reimers J, Ischinger T, et al. A randomized study of
coronary angioplasty compared with bypass surgery in patients with
1994;331:1037–43.

6 The Bypass Angioplasty Revascularization Investigation (BARI)
Investigators. Comparison of coronary bypass surgery with angioplasty

7 Rodriguez A, Mele E, Peyregne E, et al. Three year follow up the
Argentine randomized trial of percutaneous transluminal coronary
angioplasty versus coronary artery bypass surgery in multivessel disease

trials comparing coronary angioplasty with bypass surgery. Lancet
1995;346:1184–9

9 The BARI Investigators. Seven-year out come in the bypass angioplasty
revascularization investigation (BARI) by treatment and diabetic status.

survival between bypass and angioplasty for multivessel coronary

11 Jones RH, Kesler K, Phillips HR, et al. Long term survival benefits of
coronary artery bypass grafting and percutaneous transluminal
angioplasty in patients with coronary artery disease. Thorac Cardiovasc

12 Favalaro RG. Critical analysis of coronary artery bypass graft surgery: a

for coronary artery disease: initial results from the era of coronary

14 Ellis S, Fisher L, Dustman-Ellis S, et al. Comparison of coronary
angioplasty with medical treatment for single- and double-vesSEL coronary
disease with left anterior descending coronary involvement: long term
outcome based on Emory-CASS registry study. Am Heart J

15 Arvinder S, Kurbana AF, Rickards CDJ, et al. Relation between coronary
artery disease, baseline clinical variables, revascularization mode, and

16 Rodriguez A, Bernardi V, Navia J, et al. Argentina randomized study :
coronary angioplasty with stenting versus coronary bypass surgery in
patients with multiple-vessel disease (ERACI II) 30 day and one-year

angioplasty with provisional stenting versus primary stent (OCSBA3):
immediate and long term follow up results. J Am Coll Cardiol

of coronary stents versus conventional balloon angioplasty in acute

19 Selvin S. Statistical analysis of Epidemiology data. New York: Oxford

20 Egle K, Guyton R. ACC/AHA guidelines for coronary artery bypass
graft surgery: a report of the American College of Cardiology American
Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol
1999;34:1262–347.

extremity arterial disease in patients undergoing coronary
revascularization in the bypass angioplasty revascularization

22 Magovern JA, Sakett T, Magovern GJ, et al. A model that predicts
morbidity and mortality after coronary bypass graft surgery. J Am Coll
Cardiol 1996;28:1147–53.

23 Jones RH, Hannon E, Hammermeister KE, et al. Identification of
preoperative variables needed for risk adjustment of short-term mortality
after coronary artery bypass graft surgery. J Am Coll Cardiol

24 Serruys PW, Unger F, Sousa E, et al. Comparison of coronary-artery
bypass surgery and stenting for the treatment of multivessel disease.

25 Stables R. SOS results. Presented at the Annual Meeting of the American
College of Cardiology, 2001, Orlando, Florida.

26 Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for
acute threatened closure complicating percutaneous transluminal

27 Serruys PW, de Jaegere P, Kiemeneij F, et al. On behalf of the
BENESTENT Study Group: A comparison of balloon-expandable stent
implantation with balloon angioplasty in patients with coronary artery

28 Discman DL, Leon MB, Baum DS, et al. A randomized comparison of
stent placement and balloon angioplasty versus balloon angioplasty

restenosis in lesions with early loss in luminal diameter 24hours after

mammary-artery graft on 10-year survival and other cardiac events.

31 Hennessey TG, Codd MB, Donnelly S, et al. Long-term outcome following
coronary artery bypass grafting for isolated stenosis of the left anterior

randomized trial comparing stenting to internal mammary artery grafting
for proximal, isolated de novo left anterior coronary artery stenosis: the

33 Lansky AJ, Roubin GS, O Shaughnessy CD, et al, for the GR II
Randomized Clinical Trial Investigators. Randomized comparison of GR II
stenst and Palmaz-Schatz for elective treatment of coronary stenosis.

after implantation of sirolimus-coated stents in human coronary arteries: a
quantitative coronary angiography and three-dimensional intravascular